[Community-acquired bronchopneumonias in the elderly. The cost-benefit ratio in some plans of antibiotic therapy].
Community-acquired pneumonias represent the first cause of mortality due to a infectious disease, and determine more than 500,000 hospitalizations per year in the USA: moreover, they are the terminal event in many geriatric patients. Although the etiological microbial agents responsible for the majority of such pneumonias, Haemophilus influenzae and Streptococcus pneumoniae, are still sensitive to traditional antibiotics, as ampicillin, many doctors treat community acquired pneumonias with more recent and expensive antibiotics, as the third generation cephalosporins or other beta-lactamines, so enhancing the cost of the treatments, without a known, real advantage with respect to the older therapies. In this study, to evaluate whether the use of the latter antibiotics improves the outcome of community acquired pneumonias of the elderly with respect to the traditional therapy with ampicillin, we studied 123 hospitalized patients older than 65 years, affected by community-acquired pneumonia, simple or complicated. We also evaluated the cost/benefit ratio of every single treatment. Our data demonstrate that the recent antibiotics do not influence the outcome of the disease of the elderly: in particular, they do not affect the duration of the hospitalization, do not have a lower incidence of side effects, do not show a better efficacy versus ampicillin. The cost of the treatment with ampicillin is about one third of the cost of a third-generation cephalosporin treatment. We conclude that the treatment of choice for community acquired pneumonias of the elderly is ampicillin; only in few cases, as in nosocomial or in nursing homes pneumonias, third-generation cephalosporins or other antibiotics are necessary.
Scanelli
G
G
1a Divisione di Medicina Generale, Arcispedale Sant'Anna, Ferrara.
Dattola
L
L
Malagò
S
S
Padovani
F
F
D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000191:economics* / Q000627:therapeutic use; D001996:Bronchopneumonia / Q000188:drug therapy / Q000191:economics* / Q000453:epidemiology; D016009:Chi-Square Distribution; D003362:Cost-Benefit Analysis; D006801:Humans; D007558:Italy / Q000453:epidemiology; D007902:Length of Stay / Q000191:economics / Q000706:statistics & numerical data; D012074:Remission Induction; D013997:Time Factors
D000900:Anti-Bacterial Agents
Broncopolmoniti comunitarie dell'anziano. Rapporto costo-beneficio in alcuni schemi di terapia antibiotica.